
Antibiotics for Multidrug-Resistant Gram-positive Bacteria Market in China 2023
Description
Antibiotics for Multidrug-Resistant Gram-positive Bacteria Market in China 2023
Antibiotics for multidrug-resistant Gram-positive bacteria are a critical area of research and development as these types of bacteria have developed resistance to multiple types of antibiotics, making them difficult to treat. Some antibiotics that have been effective in treating certain types of multidrug-resistant Gram-positive bacteria include daptomycin, linezolid, teicoplanin, and tigecycline. The antibiotics for multidrug-resistant gram-positive bacteria market in China is anticipated to increase by USD 3.0 billion till 2029 at an average annual growth of 8.58 percent as per the latest market estimates.This industry report offers market estimates of the China market, followed by a detailed analysis of the type, and route of administration. The China market data on antibiotics for multidrug-resistant gram-positive bacteria can be segmented by type: daptomycin, linezolid, teicoplanin, tigecycline. Antibiotics for multidrug-resistant gram-positive bacteria market is further segmented by route of administration: injectable, oral.
The competitive landscape of the industry has also been examined along with the profiles of the key players Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Jiangsu Hansoh Pharmaceutical Group Co. Ltd., North China Pharmaceutical Company Ltd., Pfizer Inc., Zhejiang Hisun Pharmaceutical Co. Ltd., Zhejiang Medicine Co. Ltd.
The data-centric report focuses on market trends, status and outlook for segments. With comprehensive coverage of the market across different market segments, the report is a valuable asset for the existing players, new entrants and the future investors.
Why buy this report?
Table of Contents
37 Pages
- Part 1. Summary
- Part 2. Introduction
- Study period
- Geographical scope
- Market segmentation
- Part 3. Antibiotics for multidrug-resistant gram-positive bacteria market overview
- Part 4. Market breakdown by type
- Daptomycin
- Linezolid
- Teicoplanin
- Tigecycline
- Part 5. Market breakdown by route of administration
- Injectable
- Oral
- Part 6. Key companies
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
- North China Pharmaceutical Company Ltd.
- Pfizer, Inc.
- Zhejiang Hisun Pharmaceutical Co., Ltd.
- Zhejiang Medicine Co., Ltd.
- Part 7. Methodology
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.